Experience

Iksuda Therapeutics

• United Kingdom
• Biotechnology Research
• 1 - 100 Employee

• Chief Business Officer

  • Feb 2014 - Present

  IKSUDA is a drug development company focused on next-generation Antibody Drug Conjugates (ADCs) with market-leading profiles for hard-to-treat solid tumours. Our pipeline of ADCs is built around our proprietary conjugation platform (PermaLink®) which provides conjugation stability by design. Through PermaLink, Iksuda aims to develop more effective ADCs by leveraging the broad tumour activity associated with ultra-potent DNA-damaging payloads, combined with antibodies to clinically relevant targets. Through collaborations and partnerships, we are building a portfolio of superior ADCs. Our lead ADC targets FOLR1 and is being developed for ovarian & lung cancers. Pre-clinical data shows market leading efficacy in tumours with a range of FOLR1 expression. Show less



Atebion BDS Ltd

• Managing Director and Founder

  • Sep 2010 - Present

  I created Atebion BDS to provide solid business and investment Support for the BioPharm industry; designing and delivering asset-development pathways with clinical, technical and commercial relevance for a better probability of success. Atebion BDS enables sound investment decision-making within Pharmaceutical & Bio-Tech companies. We provide Business Development Services, Investment & Business Decision Support and Legal services, in particular to support emerging and early-stage BioTechs in shaping their drug development or platform programs & academic groups who are looking to spin-out their assets. Atebion’s focus; 1) Development of investment strategies for start-ups and emerging BioTechs, securing investment for discovery and development programmes and platform technologies, as well as research grants for defined projects 2) Defining/revising drug development strategies, enabling enhanced cost-efficiencies, commercial appropriateness, investment and collaborative licenses 3) Provision of Business development leadership and guidance for successful commercialization and license 4) Techno-commercial evaluations of assets, including small and large molecule therapeutics & enabling platforms 5) Generation of commercial feasibility reviews and start-up strategies for academic groups and University TTOs Show less



Daresbury Proteins

• United Kingdom
• Biotechnology Research
• 1 - 100 Employee

• Investment Director

  • Dec 2022 - Present

  Daresbury Proteins Ltd (DPL) specializes in mammalian recombinant protein production and cell line development which can be transferred into a third party’s cGMP setting. As an emerging biotech, DPL developed its proprietary approach while delivering various proteins for cutting-edge research. Its experience and know-how allow DPL to obtain difficult-to-express proteins in a short period of time with uncompromising quality. I represent LYVA Labs as Investor Director: LYVA Labs was established to drive economic growth through innovation across Liverpool City Region. Show less



GlycoSeLect

• United Kingdom
• Research

• Non-Executive Director

  • Aug 2013 - Present

  We specialise in developing recombinant prokaryotic lectins, (RPLs), enhanced tools for the analysis, characterisation and purification of glycosylated molecules. Our RPLs have broad applications in the biopharmaceutical and cosmeceutical industries Our RPL catalogue includes specificities for galactose, mannose and Sialic acid - fucose-specific RPLs will soon also be available. Our RPLs have significantly higher selectivity and specificity vs standard plant lectins and offer a fast, efficient, cost-effective method for glycoprofiling intact molecules, offering an accurate 'go-to' analytic prior to typical high-cost analytical technologies Show less



C4X Discovery Ltd

• United Kingdom
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Strategic Adviser

  • Jun 2015 - Dec 2017

  C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. The Company has two proprietary and synergistic software platforms "Taxonomy3®" and "Conformetrix" that provide a significant competitive advantage when combined with an experienced management team. "Taxonomy3®" is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. "Conformetrix" determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. We have a hybrid business model of wholly-owned programmes and partnerships with pharma, biotech and academics. In this role, I provided techno-commercial evaluations, market analysis and product profiling for potential drug targets, as well as discovery strategies across therapy areas, indications & drug mechanisms. Show less



Bionure

• Spain
• Biotechnology Research
• 1 - 100 Employee

• Strategic Advisor

  • Aug 2012 - Apr 2016

  Bionure is a clinical stage biotechnology company that is developing first-in-class disease-modifying neuro-protecting drugs for the treatment of degenerative, ischemic, toxic and inflammatory diseases of the nervous system, including acute optic neuritis (AON) and multiple sclerosis. Through its lead neuroprotectant, BN201, Bionure aims to become a therapeutic game changer, bringing significant benefit to millions of patients enduring serious disabilities. During my time with Bionure, I delivered • Strategic consulting, including development programme & Regulatory strategies for the optimisation of routes to market • Investment strategies, securing investment for lead candidate progression towards the clinic • General Business Development Show less



BerGenBio AS

• Norway
• Research Services

• Commercial Director (Interim)

  • Sep 2012 - Apr 2013

  Corporate strategy advice, commercial guidance, BD support, portfolio direction Corporate strategy advice, commercial guidance, BD support, portfolio direction



AstraZeneca

• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Evaluations Director

  • Jun 2006 - Sep 2010

  Techno-commercial evaluations of in-license opportunities, irresepective of development phase, therapy area or world region. Deal negotiations across geographies and therapy areas.Pipeline assessment and prioritisation on behalf of the ex-US Business, (International Sales & Marketing Organisation)

• Business Development & Portfolio Director

  • Jan 2004 - Jun 2006

  Deal negotiation for local and regional deals around the worldResponsibility for stakeholder management & deal sign-off of local & regional deals Alliance Management LeadPortfolio Review coordination on behalf of AZ International Sales & Marketing Organisation

• Global Brand Management Positions

  • Sep 1997 - Jan 2004

  Oncology, Pain & Anaesthesia Brands & portfoliosPreparation for Launch through to brands in late life-cycle



Chiroscience

• Brazil
• Retail

• Business Development & Marketing Planning Director

  • Apr 1995 - Sep 1997

  Out-license of Phase III asset, ensuring commercially viable package for major pharma. (Successful license to Zeneca (WW exc Japan) and Maruishi (Japan)). Pre-Launch market preparation Out-license of Phase III asset, ensuring commercially viable package for major pharma. (Successful license to Zeneca (WW exc Japan) and Maruishi (Japan)). Pre-Launch market preparation



Organon Teknika

• Medical Device
• 1 - 100 Employee

• National Sales Manager

  • May 1991 - Mar 1995

  Field sales management; UK pharmaceutical division strategy; Sales and product training Field sales management; UK pharmaceutical division strategy; Sales and product training